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Dear Editor,
Posterior reversible encephalopathy syndrome (PRES) pre-
sents most often with unspecific symptoms such as headache,
confusion, decreased alertness, visual dysfunction, and seizures,
which sometimes develop to status epilepticus. The diagnosis
should be suspected when some triggers (abrupt arterial hyperten-
sion, preeclampsia, immunosuppressive therapy, transplantation,
autoimmune diseases, etc.) are associated with an encephalopathy
syndrome in the context of typical magnetic resonance (MR)
findings indicative of vasogenic edema (areas of increased signal
on fluid-attenuated inversion recovery (FLAIR) predominantly
localized to the posterior cerebral hemispheres) [1]. Although its
pathogenesis is not completely understood, two hypotheses have
been postulated: the first theory consists of a rapidly developing
hypertension exceeding the upper limit of cerebral blood flow
autoregulation and leading to increased cerebral perfusion, break-
down of the blood-brain barrier with endothelial dysfunction, and
consequent extravasation of fluid and blood products into the
brain parenchyma. The second theory supports endothelial dam-
age due to direct effects of excessive circulation cytokines, pro-
moted by immunosuppressive or cytotoxic drugs, or autoimmune
disorders releasing vasoactive factors,which induce an increase of
vascular permeability and interstitial brain edema [1].
In about 90% of patients, complete remission of clinical
symptoms occurs within weeks and a restitution of abnormal
conditions in MR images is observed in about 70% of cases,
whereas complications are described in up to 10%, henceforth
leading to death in 3–6% [2]. Therefore, rapid and early iden-
tification and strict monitoring of patients threatened with the
worst outcome is needed. Because symptoms’ severity mostly
depends on the development of high intracranial pressure
(ICP), a bedside and quick tool for its detection may be par-
ticularly useful. Transorbital sonography (TOS) for optic
nerve sheath diameter (ONSD) and optic disc elevation
(ODE) assessment is a promising technique, which is able to
identify raised ICP and may represent a valid alternative to the
standard referring invasive methods for ICP measurement.
However, to date, only one report about its application in
patients with PRES is available, leaving unclear the role of
this technique for monitoring PRES [3]. Therefore, we present
a detailed description of a PRES case series in which repeated
TOS examinations played a crucial role in the diagnostic
phase and monitoring the course of the disease.
We performed TOS both acutely and over time in
four consecutive patients with PRES admitted to the
Department of Neurology at our hospital in 2018 and
2019. Clinical and demographic characteristics, neuroim-
aging aspects, diagnostic procedures, and ocular sonog-
raphy findings are thoroughly presented in the table
(Table 1). Based upon clinical features and typical
MRI findings the diagnosis of PRES was made, subse-
quently ruling out other conditions such as encephalitis,
malignancy, vasculitis, and leukoencephalopathy. All
patients underwent CSF analysis, whereas CSF pressure
was measured in two of them. A hypertensive state was
documented in all cases. Two patients recovered
completely, one only improved, and another one died
of massive cerebral edema on the second day. MR
and CT images of the deceased patient are shown in
Fig. 1. The most significant vasogenic edema is
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depicted in Fig. 2. TOS was executed using a Vivid
Seven ultrasound system (linear array probe 3.5–10
MHz; GE, Milwaukee, WI, USA) with the patients ly-
ing in supine position at 30° and the probe placed on
the temporal region of the upper eyelid. ONSD was
measured 3 mm behind the globe, defined as the dis-
tance between the hyperechogenic borders of the sub-
arachnoidal space, while ODE was gauged between the
fundus and the dome of the papilla (Fig. 3). Three
ONSD measurements were repeated in the axial plane
and their mean was used as the average value for each
eye. TOS was executed prior to lumbar puncture, except
for patient number four.
During the disease’s acute phase bilateral increases in
ONSD were documented for all patients, while ODE was
present just in two. Bilateral reduction of ONSD values was
observed in three patients over time.
Lochner et al. showed the feasibility of TOS in supporting
the diagnosis of PRES by detecting increased ICP and moni-
toring its development in a case report [4].
Both elevated ONSD and the presence of ODE are com-
patible with increased ICP as well as possible concomitant
increased permeability and edema within the optic nerve in
the acute stage of the disease. Of the two patients for whom it
was measured, CSF pressure confirmed increased ICP thus
confirming TOS findings. Compared with the ONSD dilation
that occurs hyper-acutely, ODE may take days to develop [4].
Therefore, for the deceased patient, the short time between the
onset of symptoms and TOS examination may explain why
ODE was not present. However, in our experience, we high-
light that only rarely the ONSD may not grow and sometimes
ODEmay also not be present so that ultrasonography findings
may not be separated from clinical examination and course of
the disease.














Clinical features ONSD (mm) ODE (mm)
R L R L
1, 54, F 4 130 41 Fronto-parieto-occipital lobes Headache, visual loss,
neuropsychiatric
symptoms
6.3 ± 0.1 6.0 ± 0.1 1.4 1.6
40 83 - - No symptoms 4.8 ± 0.2 4.9 ± 0.1 - -
2, 39, M 5 110 30 Parieto-occipital lobes, thalamus Headache, focal signs,
neuropsychiatric
symptoms
6.2 ± 0.1 5.9 ± 0.1 1.1 0.7
55 85 - - No symptoms 5.4 ± 0.3 5.6 ± 0.1 - -




6.7 ± 0.1 7 ± 0.1 - -
19 89 - - Mild ataxia 5.6 ± 0.2 5.6 ± 0.1 - -






6.2 ± 0.2 6.3 ± 0.1 - -
2 93 - - Dead 6.0 ± 0.1 6.0 ± 0.1 - -
ONSD, optic nerve sheath diameter (values are expressed as mean ± standard deviation); ODE, optic disc elevation;MAP, mean arterial pressure; CSF,
cerebrospinal fluid; MR, magnetic resonance; R, right; L, left; M, male; F, female; ND, not determined
Fig. 1 MR and CT imaging of patient 4. MR-T2* image showing diffuse
low signal area due to blood products and hyperintense alteration
involving predominantly and asymmetrically the frontal, insular and
parieto-occipital regions bilaterally, compatible with vasogenic edema
(a). CT brain showing diffuse effacement of sulci, consisting with cere-
bral edema (b, axial scan; c, sagittal view)
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The normalization of TOS parameters over time
corresponded to clinical improvement in the other patients,
suggesting a valid monitoring role for this technique.
TOS is increasingly used as an alternative and non-invasive
method for the detection of increased ICP. In fact, variation of
ONSD follows ICP changes, allowing bedside monitoring of
neurological conditions such as PRES in which multiple and
strict evaluations are required [5]. Monitoring is also relevant
outside the intensive care unit or similar settings where the
invasive positioning of cerebral catheters for direct ICP mea-
surements may not be possible. TOS fits perfectly in this con-
text because of its great capacity to detect increased ICP (acute
ONSD elevation and, if sufficiently extended, ODE) associat-
ed with the ability to re-normalize after ICP reduction. This
versatility makes TOS particularly suitable also for verifying
the effect of treatments and could encourage the reduction of
furthermore expensive diagnostic tools like MR and exposure
to radiation (CT), if clinical improvement matches favorable
ultrasound parameters [6].
Diagnosing PRES is challenging and established diagnostic
criteria do not exist. Clinical judgment is essential and must be
coupled with serial brain MR or CT examinations, electroenceph-
alography, and sometimes cerebral angiography. Lumbar puncture
is usually performed to rule out other conditions (i.e., encephalitis)
butmay be also particularly useful to detect and quantify increased
ICP. For early recognition of increased ICP in these patients, we
encourage the prompt use of TOS as well as the measurement of
CSF pressure, with the purpose to rapidly alert the intensive care
units or consultants for potentially taking charge.
In conclusion, this study of a small series supports the
application of TOS in patients with PRES for the identifica-
tion of increased ICP and monitoring the disease’s develop-
ment, but more evidence in larger samples is needed to further
confirm our findings.
Fig. 3 Transorbital sonography
showing measurement of the
ONSD (distance numbered as 3
while number 2 refers to the optic
nerve diameter) performed 3mm
behind the globe on the transverse
plane (a). Three-times magnifica-
tion of the optic disc in patient 2
demonstrating elevation of the
papilla (b)
Fig. 2 MR imaging of patient 1 with coronal T2 (a) and axial FLAIR (b)
images showing the diffuse and symmetrical distribution of vasogenic
edema in the cortical and subcortical area of fronto-parieto-occipital
lobes. MR imaging of patient 4 with axial FLAIR (c, d) images showing
hyperintensity of white matter representing vasogenic edema in the
fronto-temporo-parieto-occipital area
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